GlassScriptPhysician profile
Katherine Masterton
NPI 1891433785
$2,638.96
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $410 · 2023: $1,858 · 2024: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.22 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $273.91 | 2022-2024 | Imfinzi, Lynparza, Fasenra |
| Abbvie INC. | $230.50 | 2023-2024 | |
| Seagen INC. | $209.02 | 2022-2023 | Tukysa, Padcev, Adcetris |
| Novartis Pharmaceuticals Corporation | $204.00 | 2022-2024 | |
| Janssen Biotech, INC. | $152.68 | 2022-2024 | Darzalex, Imbruvica, Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $136.17 | 2022-2023 | Iclusig, Hyqvia, Vpriv |
| Lilly USA, LLC | $124.27 | 2022-2024 | Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $114.09 | 2023 | Libtayo |
| Daiichi Sankyo INC. | $113.63 | 2022-2024 | Injectafer, Enhertu |
| Genzyme Corporation | $98.72 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $97.32 | 2023 | Keytruda, Lynparza |
| Mirati Therapeutics, INC. | $92.67 | 2024 | Krazati |
| Genentech USA, INC. | $77.13 | 2023-2024 | Phesgo, Kadcyla, Perjeta |
| Incyte Corporation | $73.88 | 2023 | Jakafi |
| Jazz Pharmaceuticals INC. | $71.80 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $66.41 | 2023-2024 | Reblozyl, Pomalyst |
| Pfizer INC. | $60.91 | 2022-2023 | |
| Eisai INC. | $59.86 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.81 | 2022-2023 | |
| Coherus Oncology, INC. | $49.79 | 2022-2023 | |
| Amgen INC. | $49.22 | 2023 | Blincyto, Kyprolis, Lumakras |
| Emd Serono, INC. | $43.94 | 2022-2023 | Bavencio |
| Pharmaessentia USA Corporation | $35.26 | 2022 | |
| Tersera Therapeutics LLC | $32.42 | 2023 | Xermelo |
| Alexion Pharmaceuticals, INC. | $25.13 | 2023 | Ultomiris |
| Depuy Synthes Sales INC. | $23.80 | 2024 | Fibergraft Bg Morsels |
| G1 Therapeutics, INC. | $23.07 | 2023 | Cosela |
| Pharmacyclics LLC, An Abbvie Company | $16.40 | 2023 | Imbruvica |
| Blueprint Medicines Corporation | $15.93 | 2023 | Ayvakit |
| Taiho Oncology, INC. | $14.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Masterton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.